NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

brazen22,

Thanks for asking!

Here are some progress updates and news headlines that are a bit more recent than the 2018 article that you posted. I’m sure that you will find these recent developments representative of the greatest prospective value that the company has had since its founding:

This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt

— JAMA Oncology (@JAMAOnc) February 15, 2023

https://www.kch.nhs.uk/news/kings-team-wins-professional-excellence-award/

The MIA was approved recently and is evidence of a regulatory filing plan that has begun to unfold. Further RA applications have been under construction for a significant period of time and include a voluminous catalog of clinical data and analyses. The announcements of regulatory filings are forthcoming.

The recent MIA approval is an important step in the regulatory process, and this commercial manufacturing license will allow DCVax-L to be exported globally from Sawston. The MIA is a prerequisite of the MAA application.

“Companies applying for a marketing authorisation (also known as a product licence) need to have a manufacturer licence first. The manufacturer licence will be granted first providing the product is in the process of being approved.” —MHRA

https://finance.yahoo.com/news/northwest-biotherapeutics-advent-bioservices-announce-234600744.html

https://finance.yahoo.com/news/northwest-biotherapeutics-announces-approval-pediatric-133900403.html

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/

https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers

https://www.theguardian.com/science/2022/nov/17/im-just-carrying-on-vaccine-gives-brain-cancer-patient-years-of-extra-life

https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials

https://www.nice.org.uk/guidance/indevelopment/gid-ta10143